Tighter FDA Review Squeezing Device VCs

For over three decades, medical device investors have accepted the Food and Drug Administration's crucial role as traffic cop for their start-ups. Yes, the agency could be tough, but a green light opened a lucrative road for device companies. But venture capitalists are increasingly worried that tighter controls on regulation could endanger innovation.

By Tom Salemi

For years, venture capitalists investing in the medical device and biopharmaceutical fields have found ways to thrive even with the...

More from Archive

More from In Vivo